The potential of plants for the production and delivery of human papillomavirus vaccines

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Expert Review of Vaccines

• Publication date

  2015-06-17

• Fields of study

  Agricultural and Food Sciences, Engineering, Medicine, Biology

• Identifiers
  DOI 10.1586/14760584.2015.1037744PMID 25882610
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Mucosal Immune System for Vaccine Development

  2019cited by this paper
• Current status of viral expression systems in plants and perspectives for oral vaccines development

  2015cited by this paper
• Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

  2015cited by this paper
• Plant Virus Expression Vector Development: New Perspectives

  2014cited by this paper
• The mucosal immune system for vaccine development.

  2014cited by this paper
• The potential of Physcomitrella patens as a platform for the production of plant-based vaccines

  2014cited by this paper
• A novel multi-epitope peptide vaccine against cancer: an in silico approach.

  2014cited by this paper
• Immunological aspects of using plant cells as delivery vehicles for oral vaccines

  2014cited by this paper
• Human papillomavirus (HPV) type 16 E7 protein bodies cause tumour regression in mice

  2014cited by this paper
• Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model

  2014cited by this paper
• Expression of HPV-16 L1 capsomeres with glutathione-S-transferase as a fusion protein in tobacco plastids: An approach for a capsomere-based HPV vaccine

  2014cited by this paper
• Plant-Based Vaccines as a Global Vaccination Approach: Current Perspectives

  2014cited by this paper
• Translational Fusion and Redirection to Thylakoid Lumen as Strategies to Enhance Accumulation of Human Papillomavirus E7 Antigen in Tobacco Chloroplasts

  2014cited by this paper
• Genetically Engineered Plants as a Source of Vaccines Against Wide Spread Diseases

  2014cited by this paper
• Transgenic plants: a 5-year update on oral antipathogen vaccine development

  2014cited by this paper
• Type II heat-labile enterotoxins: structure, function, and immunomodulatory properties.

  2013cited by this paper
• Immune responses against virus and tumor in cervical carcinogenesis: treatment strategies for avoiding the HPV-induced immune escape.

  2013cited by this paper
• Virus-like particles produced in plants as potential vaccines

  2013cited by this paper
• Immunogenic assessment of plant-produced human papillomavirus type 16 L1/L2 chimaeras.

  2013cited by this paper
• Transgenic tobacco expressed HPV16-L1 and LT-B combined immunization induces strong mucosal and systemic immune responses in mice

  2013cited by this paper
• Low Cost Tuberculosis Vaccine Antigens in Capsules: Expression in Chloroplasts, Bio-Encapsulation, Stability and Functional Evaluation In Vitro

  2013cited by this paper
• Female human papillomavirus (HPV) vaccination: global uptake and the impact of attitudes.

  2013cited by this paper
• Transient expression of Human papillomavirus type 16 L2 epitope fused to N- and C-terminus of coat protein of Potato virus X in plants

  2012cited by this paper
• Potential Benefits of Second-Generation Human Papillomavirus Vaccines

  2012cited by this paper
• Primary prevention of cervical cancer: prophylactic human papillomavirus vaccines.

  2012cited by this paper
• Immunogenicity, Efficacy, Effectiveness and Overall Impact of HPV Vaccines

  2012cited by this paper
• Developing plant-based vaccines against neglected tropical diseases: where are we?

  2012cited by this paper
• Comparative analysis of recombinant Human Papillomavirus 8 L1 production in plants by a variety of expression systems and purification methods.

  2012cited by this paper
• Success of HPV vaccination is now a matter of coverage.

  2012cited by this paper
• Prevention and treatment of papillomavirus-related cancers through immunization.

  2011cited by this paper
• Human papillomavirus vaccine coverage in the United States, National Health and Nutrition Examination Survey, 2007-2008.

  2011cited by this paper
• A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.

  2011cited by this paper
• Transplastomic expression of a modified human papillomavirus L1 protein leading to the assembly of capsomeres in tobacco: a step towards cost-effective second-generation vaccines

  2011cited by this paper
• Efficient production of chimeric Human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants

  2011cited by this paper
• Immunogenicity of the Quadrivalent Human Papillomavirus (Type 6/11/16/18) Vaccine in Males 16 to 26 Years Old

  2011cited by this paper
• Just implementation of human papillomavirus vaccination

  2011cited by this paper
• Enhanced efficacy of therapeutic cancer vaccines produced by co-treatment with Mycobacterium tuberculosis heparin-binding hemagglutinin, a novel TLR4 agonist.

  2011cited by this paper
• Clinical development of plant-produced recombinant pharmaceuticals: Vaccines, antibodies and beyond

  2011cited by this paper
• Plastid expression of a double-pentameric vaccine candidate containing human papillomavirus-16 L1 antigen fused with LTB as adjuvant: transplastomic plants show pleiotropic phenotypes.

  2011cited by this paper
• Coverage and compliance of Human Papilloma Virus vaccines in Paris: demonstration of low compliance with non-school-based approaches.

  2010cited by this paper
• Human papillomavirus vaccines in plants

  2010cited by this paper
• In planta production of plant-derived and non-plant-derived adjuvants

  2010cited by this paper
• High level protein expression in plants through the use of a novel autonomously replicating geminivirus shuttle vector.

  2010cited by this paper
• Vaccine adjuvants: putting innate immunity to work.

  2010cited by this paper
• Perspectives for preventive and therapeutic HPV vaccines.

  2010cited by this paper
• Advances in saponin-based adjuvants.

  2009cited by this paper
• Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years.

  2009cited by this paper
• An E7-based therapeutic vaccine protects mice against HPV16 associated cancer.

  2009cited by this paper
• Infectious Agents and Cancer BioMed Central Review

  2009cited by this paper
• An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice

  2009cited by this paper
• Plant-made vaccine antigens and biopharmaceuticals

  2009cited by this paper
• The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix.

  2009cited by this paper
• Potato Virus X Coat Protein Fusion to Human Papillomavirus 16 E7 Oncoprotein Enhance Antigen Stability and Accumulation in Tobacco Chloroplast

  2009cited by this paper
• Development of therapeutic HPV vaccines.

  2009cited by this paper
• Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline

  2009cited by this paper
• Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines.

  2008cited by this paper
• Synthesis of a multivalent, multiepitope vaccine construct.

  2008cited by this paper
• Translational fusion of chloroplast-expressed human papillomavirus type 16 L1 capsid protein enhances antigen accumulation in transplastomic tobacco

  2008cited by this paper
• Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic.

  2008cited by this paper
• Role of Heparan Sulfate in Attachment to and Infection of the Murine Female Genital Tract by Human Papillomavirus

  2008cited by this paper
• Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum

  2007cited by this paper
• Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

  2007cited by this paper
• Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization.

  2007cited by this paper
• Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.

  2007cited by this paper
• Neutralization of Human Papillomavirus with Monoclonal Antibodies Reveals Different Mechanisms of Inhibition

  2007cited by this paper
• Human papillomavirus and HPV vaccines: a review.

  2007cited by this paper
• Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

  2007cited by this paper
• HPV vaccines: the beginning of the end for cervical cancer.

  2007cited by this paper
• Anti-cancer activity of plant-produced HPV16 E7 vaccine.

  2007cited by this paper
• Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.

  2006cited by this paper
• HPV‐mediated cervical carcinogenesis: concepts and clinical implications

  2006influential reference
• Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.

  2006cited by this paper
• Chapter 1: HPV in the etiology of human cancer.

  2006cited by this paper
• Brucella outer membrane complex-loaded microparticles as a vaccine against Brucella ovis in rams.

  2006cited by this paper
• Exploiting the plant secretory pathway to improve the anticancer activity of a plant-derived HPV16 E7 vaccine.

  2006cited by this paper
• Expression of human papillomavirus type 16 L1 protein in transgenic tobacco plants.

  2005cited by this paper
• Vaccines against human papillomavirus and cervical cancer: promises and challenges.

  2005cited by this paper
• The papillomavirus life cycle.

  2005cited by this paper
• Carcinogenicity of human papillomaviruses.

  2005cited by this paper
• Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis.

  2005cited by this paper
• The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis.

  2005cited by this paper
• The role of diet and nutrition in cervical carcinogenesis: A review of recent evidence

  2005cited by this paper
• Immune surveillance in the skin: mechanisms and clinical consequences

  2004cited by this paper
• ZYC101a for Treatment of High-Grade Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial

  2004cited by this paper
• Prevention of cervical cancer through papillomavirus vaccination

  2004cited by this paper
• Human papillomavirus vaccines for the prevention and treatment of cervical cancer.

  2004cited by this paper
• Chlamydia trachomatis and invasive cervical cancer: A pooled analysis of the IARC multicentric case‐control study

  2004cited by this paper
• Vaccination to prevent and treat cervical cancer.

  2004cited by this paper
• Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer

  2004cited by this paper
• Expression of Human papillomavirus type 16 major capsid protein in transgenic Nicotiana tabacum cv. Xanthi

  2003cited by this paper
• The male role in cervical cancer.

  2003cited by this paper
• Enhancing the immunogenicity of bioengineered Listeria monocytogenes by passaging through live animal hosts.

  2003cited by this paper
• Production of Human Papillomavirus Type 16 Virus-Like Particles in Transgenic Plants

  2003cited by this paper
• Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: A randomized clinical trial

  2003cited by this paper
• Preventative and therapeutic vaccines for cervical cancer

  2003cited by this paper
• Condom use promotes regression of human papillomavirus–associated penile lesions in male sexual partners of women with cervical intraepithelial neoplasia

  2003cited by this paper
• Oral Immunogenicity of Human Papillomavirus-Like Particles Expressed in Potato

  2003cited by this paper
• Degradation of ~ 53 Can Be Targeted by HPV E 6 Sequences Distinct from Those Required for ~ 53 Binding and TransActivation

  2003cited by this paper
• Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.

  2002cited by this paper
• Cancer Immunotherapy Using Sindbis Virus Replicon Particles Encoding a VP22–Antigen Fusion

  2002cited by this paper

• Nano-bio-encapsulation of phyto-vaccines: a breakthrough in targeted cancer immunotherapy

  2024cites this paper
• Harnessing the Potential of Plant Expression System towards the Production of Vaccines for the Prevention of Human Papillomavirus and Cervical Cancer

  2022cites this paper
• Reconceptualizing cancer immunotherapy based on plant production systems

  2017cites this paper
• Need of cost-effective vaccines in developing countries: What plant biotechnology can offer?

  2016cites this paper